Answers are grounded in this paper and cite their sources.
Chronic kidney disease (CKD) is a pressing global health concern, often intertwined with comorbid conditions such as type 2diabetes mellitus (T2DM) and cardiovascular complications. Managing CKD in T2DM patients requires a multifaceted approach,and emerging therapeutic options are increasingly essential. Finerenone, a selective nonsteroidal mineralocorticoid receptorantagonist, has shown considerable promise in addressing the intricate cardiorenal needs of these patients. To maximize theeffectiveness of this therapy, we propose the approach of “Finerenone Pentad” which can be utilized as a checklist while startingand subsequently monitoring the finerenone therapy. This structured approach offers guidance on patient selection, monitoringand outcome evaluation, ensuring a holistic approach to the care of individuals with T2DM and CKD.
No takes yet. Share an insight, caveat, or question.
SHARMA et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: